Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

Withdrawn before enrolling · Early Phase 1 · Has a placebo group

Conditions studied: Covid19

In brief

The current research is a pilot study to determine the feasibility of recruiting and retaining 40 participants diagnosed with COVID-19. The purpose is to observe the early use of fluoxetine (commonly known as Prozac) to reduce the severity of the COVID-19 illness. Fluoxetine is a drug that has been approved by the U.S. Food and Drug Administration (FDA) since 1987 for various mental health disorders.

Key facts

Study ID
NCT04570449
Run by
Milton S. Hershey Medical Center
People needed
0
Starts
2020-11-01
Expected to finish
2021-12-01
Last updated by the study team
2020-12-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.